TOPIRAMATE - INDUCED WEIGHT LOSS IN SCHIZOPHRENIA: A RETROSPECTIVE CASE SERIES STUDY
Main Article Content
Keywords
Antipsychotics, schizophrenia, topiramate, weight gain, obesity
Abstract
Objective
Atypical antipsychotics have been associated with weight gain. This study examines the efficacy of adjunctive topiramate in patients with schizophrenia and schizoaffective disorder with antipsychotic- induced weight gain.
Methods
A 2-year retrospective case analysis was performed in all 300 patients of the outpatient Special Follow-up Clinic for chronic schizophrenia and related psychoses at the Allan Memorial Institute, McGill University Health Centre (Montreal, Canada), a tertiary care University teaching hospital.
Results
10 patients met study inclusion criteria. Mean daily topiramate dose was 197.5mg (±77) (range, 125-400mg). Topiramate produced continued weight loss throughout the study duration without tolerance. Patients treated for 6 months and more had significantly higher Body Mass Index (BMI) differences than those treated for shorter durations (BMI-d6 months =-4.7±2.4; BMI-d2 months=-3.2±2.3; P=0.015). BMI changes were similar across genders.
Conclusion
This study supports topiramate use to target weight loss in stable overweight schizophrenic patients as a potential therapy that requires further investigation.
References
2. Allison DB, Fontaine KR, Heo M, et al. The
distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60(4):215-20.
3. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long -acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004;14(2):87 -92.
4. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63(12):1121 -8.
5. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic- induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65 Suppl 7:4-18.
6. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523 -9.
7. National Institutes of Health. Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus Development Conference, 30 March to 1 April 1992. Ann Intern Med 1993;119(7 Pt 2):764 -70.
8. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. A clinical trial of the efficacy and acceptability of D -fenfluramine inthe treatment of neuroleptic-induced obesity. Br J Psychiatry 1988;153:208- 13.
9. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate- treated epilepsy. Obes Res 2003;11(4):556- 62.
10. Gupta S, Masand PS, Frank BL, Lockwood KL, Keller PL. Topiramate in Bipolar and Schizoaffective Disorders: Weight Loss and Efficacy. Prim Care Companion J Clin Psychiatry 2000;2(3):96-100.
11. Krymchantowski A, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. MedGenMed 2004;6(3):48.
12. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders. Ann Gen Psychiatry 2005;4(1):5.
13. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76(2- 3):247-65.
14. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1- histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519-26.
15. Harrison PJ. Weight gain with antipsychotic drugs: the role of the 5-HT2C receptor (HTR2C) and other genes. Pharmacogenet Genomics 2005;15(4):193-4.
16. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62(4):231-8.
17. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. Obes Res 1998;6 Suppl 2:51S 209S.
18. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000;45(2):198.
19. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry
2002;63(11):1045.
20. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic- induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci 2005;59(5):613-5.
21. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther 2002;24(10):1576-84.
22. Kim JH, Yim SJ, Nam JH. A 12- week randomized, open -label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006;82(1):115-7.
23. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment wi th atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28(4):169 -75.
24. Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure 1999;8(4):235-7.
25. Stella F, Caetano D, Cendes F, Guerreiro CA. Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 2002;60(2- A):285-7.
26. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6(3):373-81.
27. Lee S, Sziklas V, Andermann F, et al. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia
2003;44(3):339 -47.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.